Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tobi Podhaler

- PMLiVE

Novartis’ Cosentyx off to a flyer in psoriasis

Year-to-date sales reach $140m for recently approved drug

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

Novartis’ Cosentyx on course for new European indications

CHMP recommends its approval to treat ankylosing spondylitis and psoriatic arthritis

National Institute for Health and Care Excellence NICE logo

NICE backs four treatments for juvenile idiopathic arthritis

Includes BMS' Orencia and AbbVie's Humira

National Institute for Health and Care Excellence NICE logo

NICE backs use of anti-cholesterol drug Ezetrol

Draft guidance reflects 'greater emphasis on managing CVD risk'

- PMLiVE

Novartis adds to immuno-oncology pipeline once again

Aims to catch up with rivals BMS and Merck & Co.

- PMLiVE

Novartis Access Scheme launches in Kenya

Expands affordable treatment options against chronic diseases

- PMLiVE

Lundbeck sways NICE with new Brintellix data

Final draft guidance now backs the major depressive disorder drug

National Institute for Health and Care Excellence NICE logo

NICE to speed up adoption of health technologies

Launches new Office for Market Access

National Institute for Health and Care Excellence NICE logo

NICE recommends Keytruda for advanced skin cancer

Second recommendation for drug in a week

- PMLiVE

Novartis signs $500m immuno-oncology deal

Gains access to Xoma's TGFb antibody programme

- PMLiVE

Novartis’ Cosentyx effective in psoriatic arthritis study

Further supports drugs ability to reduce progression of damage to joints

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links